ABOUT

miReven Pty Ltd is an Australian-based biotechnology company specialising in the design, development and commercialisation of synthetic mimics of microRNA-7 (miR-7) for the treatment of poor prognostic cancers. The company was initially established in 2010, following investment from the Medical Research Commercialisation Fund (MRCF), University of Western Australia (UWA), and the Harry Perkins Institute of Medical Research.

COMPANY OVERVIEW

SCIENCE & INNOVATION

Paving the way in innovative research and development of microRNA-based therapeutics

Read more

PARTNERSHIPS

miReven is committed to driving commercialisation through forming strategic collaborations and partnerships

PROPRIETARY TECHNOLOGY

miReven has a portfolio of granted international patents and new composition of matter patents

Read more

OUR MISSION

Development of a novel RNA-based drugĀ  mRx-7 for treatment of solid tumors.

OUR VISION

We aim to revolutionise the outcomes for patients, health professionals and families affected by cancer.

OUR VALUES

We value innovation, integrity, and passion to make a difference to our patients.